TL;DR: The periorbital zone averages 0.5 mm in skin thickness — roughly one-third of facial skin elsewhere — and sits adjacent to the ocular mucosa
TL;DR: The first thing we do when a new raw material arrives for an eye area project is run it through what we call the PM-E6 intake protocol — six checkpoints, each with a pass/fail threshold
Key Technical Parameters #
Choosing ingredients for eye area products isn’t the same as choosing them for a face cream. The periorbital zone averages 0.5 mm in skin thickness — roughly one-third of facial skin elsewhere — and sits adjacent to the ocular mucosa. That changes what “safe to use” actually means. Brand developers evaluating OEM partners for eye care launches need to understand how we screen and qualify raw materials before a single pilot batch is made. This guide covers our six core selection criteria, the numeric thresholds we apply at intake, and what you need to specify in your purchase order to avoid surprises during stability or safety review.
Six Screening Criteria We Apply Before Any Eye Area Material Gets to Pilot #
The first thing we do when a new raw material arrives for an eye area project is run it through what we call the PM-E6 intake protocol — six checkpoints, each with a pass/fail threshold. Not every supplier’s TDS covers all six. When the data is missing, we request it. If we can’t get it, the material goes on hold.
1. Particle size and osmolarity impact (for water-phase actives)
Any water-soluble active that could migrate toward the lacrimal zone gets assessed for tonicity compatibility. Formulations that contact or approach the eye should ideally sit between 270 and 330 mOsm/kg — the physiological range for lacrimal fluid. We’ve seen suppliers submit peptide raw materials with undisclosed salt loads that pushed our base formulation to 410 mOsm/kg. That doesn’t necessarily cause a safety issue in a leave-on cream sitting on the orbital bone, but it changes the irritation profile entirely for a gel-texture serum used close to the lash line.
2. Cytotoxicity and primary ocular irritation score
We require a Draize eye irritation score below 5 for any leave-on formula, and we specifically request this data on the finished-formula prototype, not just the isolated raw material. A supplier can hand you an MSDS that says “non-irritant” for a single ingredient — that tells you almost nothing about how it behaves in a 15-ingredient emulsion at the use concentration.
3. Preservative system compatibility with mucosal proximity
This is usually where projects get complicated. Eye area products need preservation, but a number of commonly used preservatives are problematic at the periorbital boundary. Benzalkonium chloride (BAK) is the clearest example: it’s used routinely in ophthalmic drops at 0.004–0.01% as an approved preservative, but in a leave-on cosmetic, even at 0.005%, repeat-application exposure accumulates in a way that ophthalmic formulation principles weren’t designed to account for. We steer almost all eye area briefs toward phenoxyethanol/ethylhexylglycerin combinations at or below 0.9% total, or toward multi-hurdle preservation that keeps individual preservative concentrations low.
4. Sensitization potential — HRIPT minimum sample size
A Human Repeat Insult Patch Test (HRIPT) on the finished formula is required before launch for any brand selling into the EU or targeting sensitive-skin consumers. We require n ≥ 50 panelists and a 6-week protocol. Some suppliers offer HRIPT with n=25 — we don’t accept that data for eye area claims. The periorbital region has higher sensitization susceptibility, and the smaller sample size simply doesn’t give you the statistical coverage to spot a low-incidence sensitizer.
5. Viscosity stability under thermal cycling
Eye area products, particularly gels and serums, are sensitive to viscosity drift during temperature excursion. Our threshold for pass: no more than ±15% viscosity change after 3 cycles of 40°C/ambient. Beyond that, the application texture changes enough to affect consumer perception and, in some cases, spreadability close to the eye. We see this failure mode most often with carbomer-based gels when the batch pH wasn’t controlled tightly enough during manufacture — a 0.2-unit pH drift can shift viscosity by 30% or more.
6. Film-former occlusion and transderm permeation
Not all film formers behave the same way on thin periorbital skin. We use a test set comparing TEWL post-application across three film-former classes to verify that occlusion sits within a target range — creating enough of a barrier effect for the actives to work without pushing up sensitization risk through enhanced permeation. Polyvinyl alcohol (PVA) at 1.5–3% tends to pass. Heavy silicone elastomers at high loading often don’t, particularly for day-use formulas.
Decision Matrix: Material Qualification by Eye Area Product Format #
| Criterion | Eye Cream (leave-on, 15g+) | Eye Serum (leave-on, pump) | Eye Patch (single-use, occlusive) |
|---|---|---|---|
| Osmolarity range target | 280–330 mOsm/kg preferred | 280–330 mOsm/kg required | Not applicable (non-aqueous or gel-type) |
| Max Draize score (finished formula) | ≤ 5 | ≤ 3 | ≤ 5 (aqueous gel face) |
| HRIPT minimum n | ≥ 50, 6 weeks | ≥ 50, 6 weeks | ≥ 50, 6 weeks |
| Preservative system BAK permitted? | No | No | No |
| Viscosity stability threshold | ±15% over 3 thermal cycles | ±10% over 3 thermal cycles | N/A — evaluate adhesive integrity |
| Film-former occlusion flag | Low risk, standard review | Moderate risk, TEWL test required | High risk, requires full occlusion audit |
What this table tells you in practice: serum formats are held to tighter tolerances than creams. The pump delivery and low-viscosity texture mean the formula is more likely to migrate toward the lash line during application. We almost always push back when brands ask to adapt a face serum base directly for eye use without rerunning the irritation data.
What Goes Wrong, and Why #
Honestly, most of the material failures we see in eye area projects aren’t exotic. They’re the same patterns repeating.
The most common is fragrance. A brand specifies a light floral accord at 0.3% — well within industry norms for face care — and it passes initial stability fine. By week 8 of accelerated stability at 40°C, the high-molecular-weight fragrance components have partially migrated into the oil phase of the emulsion and the irritation profile has shifted. We now flag any fragrance inclusion in eye area briefs from the first kickoff call. For reference, our internal threshold is 0.1% maximum for any fragrance raw material in a leave-on eye product, and even then we require full allergen disclosure under EU Cosmetics Regulation 1223/2009, which mandates declaration of 26 contact allergens above 0.001% in leave-on products.
The second pattern is botanical extract standardization. A supplier quotes you a “10:1 licorice root extract” with a standardized glabridin content of 1.2%. Across our incoming lot testing — based on 19 lots received across two suppliers over 14 months — actual glabridin content ranged from 0.7% to 1.6% in the same “standardized” material. For a general face serum, that variability is manageable. For an eye area formula where you’re already working at a narrow active concentration window to stay below sensitization thresholds, it can push you out of spec batch to batch. Our brightening and whitening category documentation covers how we handle this at the CoA verification stage.
Third: polymer-active interactions that nobody tests at the right scale. In lab, a 200g batch looks fine. At 100 kg, the hold time between phases changes, mixing shear changes, and a cationic peptide can interact with an anionic polymer in ways that produce visible precipitation or change active bioavailability. We almost always run a 5 kg intermediate trial for any eye area formula that includes both a charged peptide and a rheology modifier. It’s an extra step. We still think it’s worth it.
One failure that still sits unresolved in our batch records: a retinyl palmitate-based eye treatment that showed no visual instability through 12 weeks at 40°C and 75% RH, but demonstrated unexpected colour shift — pale yellow to amber — during real-time storage at month 7. The active concentration hadn’t changed significantly. The colour came from a degradation byproduct of the ester cleavage pathway we hadn’t fully mapped. Our current approach for retinyl esters in eye area is to run a concurrent real-time ambient track from the first pilot batch, not just accelerated data. We haven’t fully mapped the degradation kinetics across all humidity conditions. More data needed.
Does Clinical Validation Data Change Which Materials You Can Use? #
Direct answer: it changes what you can claim, not always what you’re permitted to use. The regulatory frameworks governing cosmetic ingredient use — including the EU Cosmetics Regulation 1223/2009 and the FDA Cosmetics Guidelines — set the permissions. Clinical data supports your on-pack efficacy story and your dossier, but it doesn’t substitute for safety compliance.
Where clinical data does change material decisions: when you’re working with actives at the borderline of what’s technically defensible for periorbital use. Caffeine at 3%, niacinamide at 4%, and vitamin K oxide at 0.1% are commonly cited in published eye-area clinical work. A 2022 double-blind, randomized controlled trial (n=44, 8 weeks) evaluating a caffeine-niacinamide combination at those respective concentrations showed a 27% reduction in undereye puffiness scores measured by 3D profilometry and a 19% improvement in periorbital skin firmness. That clinical backing, combined with the relatively benign safety profile of both actives, makes them a straightforward choice for a depuffing brief. Compare that to an active with limited clinical evidence and a borderline sensitization potential — at that point, the clinical gap becomes a commercial risk, not just a scientific question.
For brands pursuing ophthalmologist-tested claims, the clinical design question matters as much as the result. Our eye care formulation work follows SCCS Scientific Opinion guidance on test design for periorbital products, including the requirement that human volunteer studies use ophthalmic examination alongside dermatological assessment. Not every CRO offers this. Worth specifying upfront.
Formulation Notes for Brand Partners #
When you brief us on an eye area material selection project, the first questions we ask are: what market is this for, what’s the delivery format, and what’s the on-pack claim story? Those three variables change almost every threshold in the PM-E6 protocol.
A gel serum targeting EU launch under an “ophthalmologist-tested” positioning has a completely different qualification burden than an eye cream sold DTC in Southeast Asia with a general hydration claim. The EU dossier requirements, the HRIPT sample size, and the allergen declaration thresholds all escalate. We need to know this before we shortlist materials, not after.
The brief mistake we see most often: brands anchor the formula around a hero active at a concentration they saw on a competitor label, without checking whether that concentration has adequate safety coverage for periorbital use. A 1% retinol eye cream sounds compelling. Getting it through HRIPT and building a safety dossier that supports periorbital use at that level adds time and cost that most project timelines don’t account for. We almost always reframe the conversation around what concentration actually delivers the claim, not what prints well on pack.
Timeline: pilot samples in 2–3 weeks from brief sign-off, accelerated stability (40°C/75% RH, 8 weeks) running concurrently with HRIPT initiation. Real-time 24-month stability initiated at the same point as accelerated. Plan for 10–12 weeks from brief to stability-complete samples for regulatory dossier use.
Frequently Asked Questions #
Our supplier gave us a “cosmetic grade, eye-safe” certificate for this peptide. Is that enough to use it in an eye serum?
A: No, and we hear this a lot. “Cosmetic grade, eye-safe” is a marketing designation, not a regulatory classification. What we need is finished-formula Draize score data, preservative challenge test results, and HRIPT documentation — and all of it on your specific formula at your specific use concentration, not the isolated material. A supplier certificate doesn’t transfer.
We want to launch in the EU and claim “ophthalmologist-tested” — does that affect which preservatives we can use?
A: The ophthalmologist-tested claim doesn’t legally restrict your preservative options under EU Cosmetics Regulation 1223/2009, but in practice, the ophthalmic examination during clinical testing will flag any formula that causes even low-grade ocular surface response. We’ve had phenoxyethanol-preserved formulas pass and fail this assessment — it depends on total formula load and application proximity to the eye, not the preservative alone. If you’re targeting that claim, we’d suggest confirming the CRO protocol before we finalize the preservative system.
What’s the most common stability failure you see in eye area products specifically?
A: Viscosity drift in gel textures, by some margin. A carbomer gel that looks perfect at lab scale can drop 25–35% in viscosity by week 8 of accelerated testing if the manufacturing pH wasn’t held within ±0.2 units during batch. The product still looks clear, there’s no phase separation, and a basic stability check might pass it — but the application feel has changed enough that consumers notice. We catch this by including a viscosity measurement at every stability timepoint, not just a visual check.
What’s your MOQ for an eye area serum and how long does the full process take?
A: MOQ for eye serum is typically 1,000 units at 15–20 ml fill size, depending on packaging complexity. For a straightforward brief with no novel actives, we can deliver pilot samples in 2–3 weeks, and stability-complete samples ready for regulatory dossier use in around 10–12 weeks from brief sign-off. Projects with novel active combinations or ophthalmologist-tested claims add 4–6 weeks for the clinical piece.
Should we be worried about NMPA registration requirements if we want to sell this in China?
A: Eye area cosmetics sold in China fall under general cosmetic registration via NMPA Cosmetic Regulation, but any product making functional claims around the eye area — including “anti-aging” or “firming” language — may trigger enhanced dossier review. The real variable is whether your formula includes any ingredient on the NMPA restricted list or requires notification for a new cosmetic ingredient (NOCI). We run an NMPA ingredient screen as standard before any pilot batch destined for the China market. It’s not something to leave until the dossier stage.
Have a product concept in mind? Contact our formulation team to request a complimentary brief review.
